Release Details

SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging proprietary next-generation, non-viral gene engineering technologies to create life-saving therapeutics, today announced that an update from the first five cohorts of an ongoing Phase 1 study of P-BCMA-101, Poseida’s lead autologous CAR-T therapeutic candidate for patients with relapsed/refractory multiple myeloma, will be presented at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego on December 3, 2018.

Presentation Title: Efficacy and Safety of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory Multiple Myeloma
Abstract Number: 1012
Date and Time: 6:15 - 7:45 p.m. PT, Monday, December 3, 2018 
Location: Ballroom 20D, San Diego Convention Center

About P-BCMA-101
P-BCMA-101 is an autologous CAR-T therapeutic candidate being developed to treat patients with relapsed/refractory multiple myeloma. P-BCMA-101 targets cells that express B cell maturation antigen, or BCMA, which is expressed on essentially all multiple myeloma cells. P-BCMA-101 is engineered with Poseida’s non-viral piggyBac™ DNA Modification System, resulting in a high percentage of a long-lived, self-renewing type of T cells called T stem cell memory cells (T_SCM). Previously reported preliminary results from the company’s ongoing Phase 1 clinical trial suggested that P-BCMA-101 may have improved response rates with a favorable safety profile compared to published results from clinical trials of other CAR-T therapies at similar doses.  Low to no levels of cytokine release syndrome or neurotoxicity had been seen as of the date the previous results were reported. The Phase 1 study is funded in part by the California Institute for Regenerative Medicine.

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biotechnology company leveraging proprietary next-generation non-viral, gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. The company is developing a wholly-owned pipeline of autologous and allogeneic CAR-T product candidates, initially focused on the treatment of hematological malignancies and solid tumors. Poseida’s product candidates are designed to address the limitations of other CAR-T therapies, including duration of response, the ability to treat solid tumors and safety concerns. P-BCMA-101 is Poseida’s lead CAR-T therapy currently in Phase 1 clinical development for the treatment of relapsed/refractory multiple myeloma.

Corporate Contacts:
Marcy Graham
VP, Corporate Affairs
Poseida Therapeutics, Inc.
858-779-3108
mgraham@poseida.com

Jason Spark
Canale Communications
619-849-6005
Jason@canalecomm.com